You can buy or sell Immunomedics and other stocks, options, ETFs, and crypto commission-free!
Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. Read More The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.
Morris Plains, New Jersey
52 Week High
52 Week Low
Tech, healthcare mega deals boost virus-stricken M&A market
(Reuters) - After adapting to working from home in the COVID-19 pandemic, cash-rich technology and healthcare companies have now mastered dealmaking from home.
Dealmakers See $69 Billion of M&A in Year’s Busiest Weekend
(Bloomberg) -- A blockbuster Sunday of takeovers has bled into Monday for the fastest start to a week for global dealmaking this year. Companies led by Japanes
— per share
Expected Oct 28, After Hours
Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal
(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer
Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics
(Reuters) - Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acces
Gilead To Explore Trodelvy Drug Against Different Cancers After $21B Merger With Immunomedics
After initial reports emerged on Saturday about a potential acquisition deal, Gilead Sciences Inc (NASDAQ: GILD) confirmed that it's set to purchase Immunomedic
Gilead to buy cancer drugmaker Immunomedics for $21 billion
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California (Reuters) - Gilead Scie
Gilead reaches $21 billion deal for Immunomedics
Gilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of th
Gilead to buy Immunomedics in a $21 bln deal
Sept 13 (Reuters) - Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's por